The capabilities that support these activities are often shared, so the same infrastructure helping researchers understand how materials perform in reactor environments also supports advanced manufacturing, isotope production and the development of new medical treatments and materials.
Investments in nuclear research benefits multiple sectors simultaneously. One area where there may be a significant opportunity is in strengthening a national accessible network of nuclear research infrastructure and capabilities. Internationally, countries with strong nuclear sectors often support national user facilities by sharing infrastructure and enabling universities, industry, hospitals, utilities, government laboratories and entrepreneurs to have access and, importantly, the opportunity to work together. Importantly, nuclear infrastructure carries significant regulatory safety, security and operating requirements. As a result, there are advantages to building critical mass around existing centres of expertise while ensuring broad national access and collaboration.
One capability that deserves particular attention is neutron science. There is neutron scarcity in the world, yet neutrons remain one of the most powerful tools supporting diverse research areas, from energy systems to batteries, aerospace, quantum materials and more. The Canadian Neutron Beam Laboratory at McMaster University represents an important step in rebuilding that capability in Canada. More broadly, the CNBL can be viewed as strategic research infrastructure supporting innovation across multiple sectors.
Alongside neutron science, there are significant opportunities associated with innovation and commercialization. One area where I believe this opportunity is particularly visible is radiopharmaceuticals. We have a long and successful history in medical isotopes. The opportunity, however, is not only in producing isotopes, but also in developing the diagnostic agents and therapies themselves. That is the vision behind the McMaster institute for radiopharmaceutical imaging and therapy, or MIRIT. Through MIRIT, researchers, clinicians, radiochemists, hospitals and industry partners will work together, encompassing the entire radiopharmaceutical pipeline, from isotope production to clinical trials.
